Abstract
mRCC treatment has expanded to include several ICIs and combinations with targeted kinase inhibitors. However, only clinical criteria has been validated to predict for ICI treatment responses. We previously described a highly sensitive CTC assay with multivalent binding, e-selectin induced cell rolling, and multiple antibody ligands. We prospectively evaluated whether CTC change would predict for ICI response in mRCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
